Minireviews
Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1696-1708
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1696
Table 1 Main published data from various minimally invasive treatment options
Ref.
Study design
Treatment
No. of patients
Outcomes
Complications/Adverse events
Hsiao et al[13]Single-center, single-arm, retrospectiveIRE9Median overall survival: 26 mo; progression-free survival: 18 moNone reported
Martin et al[14]Single-center, single-arm, retrospectiveIRE26Median survival without biliary drainage: 305 d (range 92–458); disease-free: 11.5%Complications: 3/26 (11.5%; severe 7.7%)
Li et al[18]Single-center, comparative, retrospectivePDT + stent vs stent-only 62 (30 vs 32)Median survival: PDT + stent 14.2 vs stent-only 9.8 mo, P = 0.003Adverse events: 24 (38.7%) vs 20 (29.0%), P = 0.239
Mizandari et al[22]Single-center, single-arm, retrospectiveEndobiliary RFA39Median survival: 89.5 d (range 14-260) None reported
Andrašina et al[27]Single-center, prospective, multimodal oncological therapyTACE or IA chemotherapy with or without SC vs IV SC40 (17 vs 23)Median overall survival: 13.5 mo (range, 11.0-18.8 mo). Median overall survival IA: 25.2 mo (range, 15.2-31.3 mo) vs IV SC 11.5 mo (range, 8.5-12.6 mo) in (P < 0.05)None reported